Nanobac, Eureka Genomics Ink Definitive Merger Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Nanobac Pharmaceuticals and Eureka Genomics have inked a definitive merger pact, under which Eureka shareholders will own 85 percent of the merged firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.